Share on StockTwits

Galmed Pharmaceuticals’ (NASDAQ:GLMD) lock-up period is set to expire on Tuesday, September 9th. Galmed Pharmaceuticals had issued 2,837,400 shares in its IPO on March 13th, Stock Ratings Network reports. The total size of the offering was $38,304,900 based on an initial share price of $13.50. After the expiration of Galmed Pharmaceuticals’ lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Shares of Galmed Pharmaceuticals (NASDAQ:GLMD) remained flat at $6.76 during trading on Thursday. Galmed Pharmaceuticals has a 52-week low of $5.83 and a 52-week high of $18.73. The stock has a 50-day moving average of $7.38 and a 200-day moving average of $8.68. The company’s market cap is $75.0 million.

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugates (NASDAQ:GLMD).

Receive News & Ratings for Galmed Pharmaceuticals Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.